TE
IOVA icon

Tema ETFs’s Iovance Biotherapeutics IOVA Stock Holding History

Tema ETFs’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
280,048
+95,933
+52% +$364K 0.04% 266
2026
Q1 		$646K Buy
+184,115
New +$589K 0.04% 314
2025
Q4 		– Sell
-173,872
Closed -$377K – 584
2025
Q3 		$377K Buy
+173,872
New +$411K 0.03% 427

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Tema ETFs's IOVA Position: Q2 2026 in Review

Tema ETFs increased its Iovance Biotherapeutics (IOVA) stake by 52% in Q2 2026, buying an estimated $364K and bringing the position to 280,048 shares worth $1.17M. The position accounts for 0.04% of the portfolio, ranked #266.

Tema ETFs first reported a position in IOVA in Q3 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Tema ETFs held 280,048 shares of Iovance Biotherapeutics worth $1.17M as of Q2 2026.
  • Tema ETFs bought 95,933 Iovance Biotherapeutics shares in Q2 2026, an estimated $364K.
  • Iovance Biotherapeutics made up 0.04% of Tema ETFs's portfolio in Q2 2026, its #266 holding.
  • Tema ETFs first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.